Exploitation of localized surface plasmon resonance of silver/gold nanoparticles for the fluorescence quantification of angiotensin II receptor antagonists in their tablets and bio-samples,New Journal of Chemistry

当前位置： X-MOL 学术 › New J. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Exploitation of localized surface plasmon resonance of silver/gold nanoparticles for the fluorescence quantification of angiotensin II receptor antagonists in their tablets and bio-samples
New Journal of Chemistry ( IF 2.7 ) Pub Date : 2018-12-04 00:00:00 , DOI: 10.1039/c8nj05218b
N. A. Alarfaj _{1,

2,

3,

4,

5} , S. A. Altamimi _{1,

2,

3,

4,

5} , M. F. El-Tohamy _{1,

2,

3,

4,

5} , A. M. Almahri _{1,

2,

3,

4,

5}

Affiliation

The present study suggested six different fluorimetric systems for the determination of three angiotensin II receptor antagonists, candesartan cilexetil (CDC), valsartan (VAL) and telmisartan (TEL) in their bulk and pharmaceutical dosage forms. The fluorescence intensities (FIs) were recorded by measuring the high catalytic potential activity of silver or gold nanoparticles (AgNPs or AuNPs) at λ_ex 525, 420 and 330 nm and λ_em 555, 490 and 400 nm for CDC, VAL and TEL, respectively. All experimental measurements were carried out under optimum conditions using the CDC–Tb(III)–AgNPs, CDC–Tb(III)–AuNPs, VAL–Eu(III)–AgNPs, VAL–Eu(III)–AuNPs, TEL–SDS–AgNPs and TEL–SDS–AuNPs systems. The fluorescence (FL) signals displayed linear concentration ranges of 0.01–300, 0.02–120 and 2.0–30 ng mL⁻¹ for CDC, VAL and TEL in the presence of AgNPs, respectively, and 0.05–60, 0.1–80 and 0.1–250 ng mL⁻¹ for the same drugs in the presence of AuNPs, respectively. The influence of possible coexisting species and additives was tested. ICH guidelines were followed to validate the developed methods. All suggested FL systems were successfully used to monitor the investigated drugs in bulk, tablets and bio-samples. The obtained data were compared with those of other reported methods revealing high agreement.

中文翻译：

利用银/金纳米颗粒的局部表面等离振子共振对片剂和生物样品中血管紧张素II受体拮抗剂的荧光定量

本研究建议了六种不同的荧光测定系统，用于测定三种散装和药物剂型的血管紧张素II受体拮抗剂坎地沙坦cilexetil（CDC），缬沙坦（VAL）和替米沙坦（TEL）。的荧光强度（FIS）通过在测量银或金纳米颗粒（的AgNPs或金纳米粒子）的高催化潜在活性记录λ _EX 525，420和330纳米和λ _EM 555，490和400nm为CDC，VAL和TEL，分别。所有实验测量均在最佳条件下使用CDC–Tb（III）–AgNPs，CDC–Tb（III）–AuNPs，VAL–Eu（III）–AgNPs，VAL–Eu（III）进行）-AuNP，TEL-SDS-AgNP和TEL-SDS-AuNPs系统。在存在AgNP的情况下，CDC，VAL和TEL的荧光（FL）信号线性浓度范围分别为0.01–300、0.02–120和2.0–30 ng mL ^-1，以及0.05–60、0.1–80和0.1的线性浓度范围对于存在AuNP的相同药物，分别为–250 ng mL ^-1。测试了可能共存的物种和添加剂的影响。遵循ICH指南来验证开发的方法。所有建议的FL系统均已成功用于监测散装，片剂和生物样品中所研究的药物。将获得的数据与显示高度一致性的其他报道的方法进行了比较。

更新日期：2018-12-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11